The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are conducted free of charge for Awardees.
The most recent awardees are: Dr. Young Jik Kwon, University of California, Irvine & PharmaResearch Products, Co., Ltd. (Bundang, South Korea); Dr. Gregory Lanza, Washington University & Alembic Pharmaceuticals, Ltd.; and Sitka Biopharma, Inc. Please click here to download a pdf of the announcement.
The NCL accepts applications four times per year, in March, June, September and December. If you’re interested in applying for the next application cycle, please download our White Paper application here: https://ncl.cancer.gov/working-ncl/ncl-assay-cascade-application-process. The next deadline is June 1, 2021. If you have any questions about the process, please feel free to contact us at email@example.com.